Polyrizon Reports Positive Naloxone Hydrogel Mucoadhesion Results
Ticker: PLRZ · Form: 6-K · Filed: Dec 3, 2025 · CIK: 1893645
| Field | Detail |
|---|---|
| Company | Polyrizon Ltd. (PLRZ) |
| Form Type | 6-K |
| Filed Date | Dec 3, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | mixed |
Sentiment: mixed
Topics: drug-development, medical-devices, press-release
TL;DR
Polyrizon's naloxone hydrogel shows better mucoadhesion than existing product. Big win for overdose treatment.
AI Summary
Polyrizon Ltd. announced on December 3, 2025, positive mucoadhesion results for its intranasal naloxone hydrogel. These results were compared against a currently marketed intranasal naloxone product, indicating potential advantages for Polyrizon's formulation. The company is a foreign private issuer based in Raanana, Israel, and filed this report under Form 6-K.
Why It Matters
Positive mucoadhesion results could lead to improved drug delivery and efficacy for intranasal naloxone, a critical medication for opioid overdose reversal.
Risk Assessment
Risk Level: medium — The filing reports positive results but does not include financial data or details on regulatory approval status, leaving significant unknowns about commercialization potential.
Key Players & Entities
- Polyrizon Ltd. (company) — Registrant
- December 3, 2025 (date) — Press release date
- Intranasal Naloxone Hydrogel (product) — Drug formulation
- Intranasal Naloxone (product) — Marketed product for comparison
- Raanana, Israel (location) — Company headquarters
FAQ
What specific metrics were used to demonstrate 'positive mucoadhesion results'?
The filing incorporates a press release that states positive mucoadhesion results but does not detail the specific metrics or quantitative data used in the comparison.
When was the press release detailing these results issued?
The press release was issued on December 3, 2025.
What is the primary purpose of intranasal naloxone?
Intranasal naloxone is used to reverse the effects of an opioid overdose.
What form does Polyrizon's new naloxone product take?
Polyrizon's new naloxone product is an intranasal hydrogel.
What type of SEC filing is this and what does it typically contain?
This is a Form 6-K, which is a Report of Foreign Private Issuer that typically includes information that the company has made or is required to make public in its home country, file with a stock exchange, or distribute to its security holders.
Filing Stats: 270 words · 1 min read · ~1 pages · Grade level 14 · Accepted 2025-12-03 16:01:28
Filing Documents
- ea0268323-6k_polyrizon.htm (6-K) — 11KB
- ea026832302ex99-1_polyrizon.htm (EX-99.1) — 12KB
- 0001213900-25-117808.txt ( ) — 23KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Polyrizon Ltd. Date: December 3, 2025 By: /s/ Tomer Izraeli Name: Tomer Izraeli Title: Chief Executive Officer 2